Search Results

You are looking at 1 - 10 of 148 items for :

  • "breast carcinoma" x
  • Refine by Access: All x
Clear All
Full access

Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary

Jennifer Shih, Babar Bashir, Karen S. Gustafson, Mark Andrake, Roland L. Dunbrack, Lori J. Goldstein, and Yanis Boumber

, including lung and breast carcinomas. 1 , 2 First-line treatment of lung adenocarcinomas that have a sensitizing EGFR mutation or ALK rearrangement includes the use of a tyrosine kinase inhibitor, such as erlotinib or crizotinib, whereas ceritinib is

Full access

Breast Cancer Screening and Diagnosis

Therese B. Bevers, Benjamin O. Anderson, Ermelinda Bonaccio, Sandra Buys, Mary B. Daly, Peter J. Dempsey, William B. Farrar, Irving Fleming, Judy E. Garber, Randall E. Harris, Alexandra S. Heerdt, Mark Helvie, John G. Huff, Nazanin Khakpour, Seema A. Khan, Helen Krontiras, Gary Lyman, Elizabeth Rafferty, Sara Shaw, Mary Lou Smith, Theodore N. Tsangaris, Cheryl Williams, and Thomas Yankeelov

. Women Aged 35 Years or Older With a 5-Year Risk of Invasive Breast Carcinoma Greater Than or Equal to 1.7%: For women aged 35 and older, a risk assessment tool is available to identify those who are at increased risk. The NCI and the National Surgical

Full access

Fine-Needle Aspiration Biopsy of Palpable Breast Masses: Patterns of Clinical Use and Patient Experience

Amy Ly, Jill C. Ono, Kevin S. Hughes, Martha B. Pitman, and Ronald Balassanian

situ (ALH/LCIS), fibromatosis, unclassified fibroepithelial lesion, and nonmalignant Phyllodes tumors. Malignant cases contained ductal carcinoma in situ (DCIS) with and without associated invasive breast carcinoma (IBC). Fifty MGH-FNAB cases were

Full access

Breast Cancer Risk Reduction

Therese B. Bevers, Deborah K. Armstrong, Banu Arun, Robert W. Carlson, Kenneth H. Cowan, Mary B. Daly, Irvin Fleming, Judy E. Garber, Mary Gemignani, William J. Gradishar, Helen Krontiras, Swati Kulkarni, Christine Laronga, Loretta Loftus, Deborah J. MacDonald, Martin C. Mahoney, Sofia D. Merajver, Ingrid Meszoely, Lisa Newman, Elizabeth Pritchard, Victoria Seewaldt, Rena V. Sellin, Charles L. Shapiro, and John H. Ward

C Lieberman PH . Lobular carcinoma in situ of the breast. Detailed analysis of 99 patients with average follow-up of 24 years . Am J Surg Pathol 1978 ; 2 : 225 – 251 . 39. Haagensen CD Bodian C Haagensen DE Jr . Breast Carcinoma

Full access

Perspectives on Margins in DCIS: Pathology

Susan Lester

. Molecular clonality determination of ipsilateral recurrence of invasive breast carcinomas after breast-conserving therapy: comparison with clinical and biologic factors . Am J Clin Pathol 2005 ; 123 : 679 – 689 . 13. Amari M Moriya T Ishida T

Full access

Germline PALB2 Variants and PARP Inhibitors in Endometrial Cancer

Michael A. Cilento, Nicola K. Poplawski, Sellvakumaram Paramasivam, David M. Thomas, and Ganessan Kichenadasse

Research; AO, anaplastic oligodendroglioma; CUP, cancer of unknown primary; ESC, endometrial serious adenocarcinoma; HGSOC, high-grade serous ovarian carcinoma; IBC, invasive breast carcinoma; ICC, intrahepatic cholangiocarcinoma; IDC, invasive ductal

Full access

Evolving Concepts in the Management of Lobular Neoplasia

Benjamin O. Anderson, Kristine E. Calhoun, and Eric L. Rosen

epithelium of the human breast . Pathol Annu 1982 ; 17 : 319 – 328 . 19. Breslow A Brancaccio M . Intracellular mucin production by lobular breast carcinoma cells . Arch Pathol Lab Med 1976 ; 100 : 620 – 621 . 20. Eusebi V Betts C

Full access

Oncology Research Program

maximum tolerated dose (MTD) of temsirolimus with daily neratinib and to determine the safety and efficacy of this combination for patients with advanced breast carcinoma. Patients with trastuzumab-refractory HER2-amplified disease or triple

Full access

A Distributed Network for Intensive Longitudinal Monitoring in Metastatic Triple-Negative Breast Cancer

C. Anthony Blau, Arturo B. Ramirez, Sibel Blau, Colin C. Pritchard, Michael O. Dorschner, Stephen C. Schmechel, Timothy J. Martins, Elisabeth M. Mahen, Kimberly A. Burton, Vitalina M. Komashko, Amie J. Radenbaugh, Katy Dougherty, Anju Thomas, Christopher P. Miller, James Annis, Jonathan R. Fromm, Chaozhong Song, Elizabeth Chang, Kellie Howard, Sharon Austin, Rodney A. Schmidt, Michael L. Linenberger, Pamela S. Becker, Francis M. Senecal, Brigham H. Mecham, Su-In Lee, Anup Madan, Roy Ronen, Janusz Dutkowski, Shelly Heimfeld, Brent L. Wood, Jackie L. Stilwell, Eric P. Kaldjian, David Haussler, and Jingchun Zhu

&E, original magnification x10). (D) Images shows a pulmonary infarct (H&E, original magnification x2). (E) Magnified view of Figure 6B (H&E, original magnification x10). (F) In many of these arteries, there is near occlusion of the lumen by breast carcinoma

Full access

Indications for Breast MRI in the Patient with Newly Diagnosed Breast Cancer

Constance D. Lehman, Wendy DeMartini, Benjamin O. Anderson, and Stephen B. Edge

Edited by Kerrin G. Robinson

of symptomatic primary breast cancer with MR imaging . AJR Am J Roentgenol 1997 ; 169 : 417 – 424 . 6 Fischer U Kopka L Grabbe E . Breast carcinoma: effect of preoperative contrast-enhanced MR imaging on the therapeutic approach